In this groundbreaking study of cancer patients treated with immunotherapy for stage IV cancer, ReD has illuminated the particular state of patients who survive longer than their initial prognosis. These patients are able to achieve a state of normalcy, despite having a terminal condition.
Read MoreSuccesful companies design for the everyday life of the consumer, and not just the clinical trial
Read MoreJun Lee and Mikkel Brok-Kristensen, Partners at ReD Associates, argue that developers should stop trying to develop wearables for life, but instead focus on how they can teach the wearer how to live without them.
Read MorePartner at ReD Associates, Mikkel Brok-Kristensen, explains how Coloplast successfully changed their innovation process towards a nonlinear and non-hypothesis driven approach.
Read MoreIn this article, ReD Associates’ Charlotte Vangsgaard, Mikkel Brok-Kristensen and Mads Holme discuss the need to take a patient-centric approach to guide early drug development and clinical trials.
Read MoreHow can design help solve social problems? Alice Rawsthorn writes about Copenhagen’s initiative to reduce sick leave in the New York Times with the help of the innovation consultancy ReD Associates.
Read MoreDanes’ sick leave amounts to the equivalent of 150,000 full-time jobs, which is hurting companies’ bottom line. A project by ReD Associates found that it is possible to reduce sick leave by 60 percent.
Read More